216 related articles for article (PubMed ID: 11213012)
1. Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists.
Cheng YM; Chou CY; Huang SC; Lin HC
BJOG; 2001 Jan; 108(1):95-102. PubMed ID: 11213012
[TBL] [Abstract][Full Text] [Related]
2. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
[TBL] [Abstract][Full Text] [Related]
3. Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pretreated women.
Vollenhoven BJ; Pearce P; Herington AC; Healy DL
Clin Endocrinol (Oxf); 1994 Apr; 40(4):537-44. PubMed ID: 8187322
[TBL] [Abstract][Full Text] [Related]
4. Association of the shrinkage of uterine leiomyoma treated with GnRH agonist and deletion of long arm of chromosome 7.
Takahashi K; Kawamura N; Tsujimura A; Ichimura T; Ito F; Ishiko O; Ogita S
Int J Oncol; 2001 Jun; 18(6):1259-63. PubMed ID: 11351260
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro.
Chung YJ; Chae B; Kwak SH; Song JY; Lee AW; Jo HH; Lew YO; Kim JH; Kim MR
Int J Med Sci; 2014; 11(3):276-81. PubMed ID: 24516352
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas.
Ishihara H; Kitawaki J; Kado N; Koshiba H; Fushiki S; Honjo H
Fertil Steril; 2003 Mar; 79 Suppl 1():735-42. PubMed ID: 12620485
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production.
Britten JL; Malik M; Levy G; Mendoza M; Catherino WH
Fertil Steril; 2012 Nov; 98(5):1299-307. PubMed ID: 22901846
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells.
Wang Y; Matsuo H; Kurachi O; Maruo T
Eur J Endocrinol; 2002 Mar; 146(3):447-56. PubMed ID: 11888853
[TBL] [Abstract][Full Text] [Related]
9. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas.
Vu K; Greenspan DL; Wu TC; Zacur HA; Kurman RJ
Hum Pathol; 1998 Apr; 29(4):359-63. PubMed ID: 9563785
[TBL] [Abstract][Full Text] [Related]
10. Enhanced deoxyribonucleic acid damage and repair but unchanged apoptosis in uterine leiomyomas treated with gonadotropin-releasing hormone agonist.
Huang SC; Chou CY; Lin YS; Tsai YC; Hsu KF; Liu CH; Huang KE
Am J Obstet Gynecol; 1997 Aug; 177(2):417-24. PubMed ID: 9290461
[TBL] [Abstract][Full Text] [Related]
11. Decreased prolactin secretion by explant cultures of fibroids from women treated with a gonadotropin-releasing hormone agonist.
Rein MS; Friedman AJ; Heffner LJ
J Clin Endocrinol Metab; 1990 Jun; 70(6):1554-8. PubMed ID: 2112150
[TBL] [Abstract][Full Text] [Related]
12. Metachromasia of the endocervical epithelium in women treated with gonadotropin releasing hormone agonist.
Morimura M; Ishiko O; Honda KI; Sumi T; Kawamura N; Wakasa K; Haba T; Ogita S
Int J Mol Med; 2001 Sep; 8(3):319-21. PubMed ID: 11494062
[TBL] [Abstract][Full Text] [Related]
13. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones.
Malik M; Britten J; Cox J; Patel A; Catherino WH
Fertil Steril; 2016 Jan; 105(1):214-24. PubMed ID: 26409322
[TBL] [Abstract][Full Text] [Related]
15. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas.
Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M
Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824
[TBL] [Abstract][Full Text] [Related]
16. Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues.
van der Spuy ZM; Wood M; Fieggen G; Hendricks MS
S Afr Med J; 1993 Jul; 83(7):510-3. PubMed ID: 8211493
[TBL] [Abstract][Full Text] [Related]
17. Changes in insulin sensitivity during GnRH agonist treatment in premenopausal women with leiomyoma.
Matsui S; Yasui T; Tani A; Kunimi K; Uemura H; Yamamoto S; Kuwahara A; Matsuzaki T; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M
Clin Chim Acta; 2012 Jun; 413(11-12):960-5. PubMed ID: 22366120
[TBL] [Abstract][Full Text] [Related]
18. Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment.
Ito F; Kawamura N; Ichimura T; Tsujimura A; Ishiko O; Ogita S
Fertil Steril; 2001 Jan; 75(1):125-30. PubMed ID: 11163826
[TBL] [Abstract][Full Text] [Related]
19. GnRH agonists before surgery for uterine leiomyomas. A review.
Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
[TBL] [Abstract][Full Text] [Related]
20. Involvement of annexin V in the antiproliferative effect of GnRH agonist on cultured human uterine leiomyoma cells.
Yamamoto H; Sato H; Shibata S; Murata M; Fukuda J; Tanaka T
Mol Hum Reprod; 2001 Feb; 7(2):169-73. PubMed ID: 11160843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
